Peter Iversen
Aarhus University · 394 works · 13,813 citations · h-index 54
Top works
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- A Point System for Selecting Operative Candidates
- Value of postvoid residual urine determination in evaluation of prostatism
- Analysis of Presenting Symptoms in Prostatism
- Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study.
- Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
- Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
- BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP
- A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer
- Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program
- A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer
- The Relevance of Minimum Urethral Resistance in Prostatism
- Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- BICALUTAMIDE 150 MG IN ADDITION TO STANDARD CARE IN PATIENTS WITH LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM THE SECOND ANALYSIS OF THE EARLY PROSTATE CANCER PROGRAM AT MEDIAN FOLLOWUP OF 5.4 YEARS
- Significance of Prostatic Weight in Prostatism
- Spontaneous uroflowmetry in prostatism
- Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
- BICALUTAMIDE (150 MG) VERSUS PLACEBO AS IMMEDIATE THERAPY ALONE OR AS ADJUVANT TO THERAPY WITH CURATIVE INTENT FOR EARLY NONMETASTATIC PROSTATE CANCER: 5.3-YEAR MEDIAN FOLLOWUP FROM THE SCANDINAVIAN PROSTATE CANCER GROUP STUDY NUMBER 6
- Transurethral Prostatic Resection in the Treatment of Prostatism with High Urinary Flow